21
ALL21
Tris Pharma IncYear
21
ALL3
20253
20243
20236
20223
20213
2020DEALS // DEV.
21
ALL8
Deals13
DevelopmentsCountry
19
ALL19
U.S.A21
ALL1
Athena Bioscience3
Inapplicable1
KYE Pharmaceuticals1
Medison Pharma1
National Institute on Drug Abuse9
Not Applicable1
Park Therapeutics1
Pediatrix Therapeutics1
Perigon Pharmacy 3601
Teva Pharmaceutical Industries1
Tris Pharma IncTherapeutic Area
21
ALL1
Cardiology/Vascular Diseases7
Neurology12
Psychiatry/Psychology1
SleepStudy Phase
21
ALL11
Approved5
Phase III1
Phase II1
IND Enabling1
Preclinical2
UndisclosedDeal Type
11
ALL2
Acquisition1
Agreement1
Collaboration1
Funding3
Inapplicable1
Licensing Agreement2
PartnershipProduct Type
21
ALL3
Other Small Molecule17
Small molecule1
UndisclosedDosage Form
13
ALL1
Extended Release Tablet1
Extended-release tablet1
Intranasal Powder1
Oral1
Oral Tablet1
Oral Tablet, Film Coated1
Suspension, Extended Release1
Tablet, Chewable3
Tablet, Extended Release2
Tablet, Film CoatedLead Product
21
ALL5
Amphetamine7
Cebranopadol1
Clonidine5
Methylphenidate Hydrochloride1
Sodium Oxybate1
TRN-2611
UndisclosedTarget
5
ALL1
GABA B receptor1
MAO3
NOP/MOP receptorLead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris’ Cebranopadol Shows Positive Phase 3 Results in Acute Pain
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Reports Low Abusability for Cebranopadol Pain Therapy
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Presents Positive ALLEVIATE-1 Trial Data for Cebranopadol in Acute Pain
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2025
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tris Pharma Expands Global ADHD Drug Availability with New Approvals
Details : Quillivant (methylphenidate HCl) is a dopamine/norepinephrine reuptake inhibitor, which is indicated for the treatment of attention deficit hyperactivity disorder in patients aged 6 to 65 years.
Product Name : Quillivant
Product Type : Small molecule
Upfront Cash : Not Applicable
November 19, 2024
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tris Pharma Starts ALLEVIATE-1 and 2 Trials of Cebranopadol for Pain Treatment
Details : TRN-228 (cebranopadol) is a first-in-class therapy, with a novel mechanism of action that targets both NOP and MOP receptor, called dual-NMR agonist for the treatment of multiple types of pain.
Product Name : TRN-228
Product Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2024
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clonidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tris Pharma Gets FDA Approval for ONYDA XR, First Liquid ADHD Medication
Details : FDA has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension for the treatment of ADHD in pediatric patients six years and older.
Product Name : Onyda
Product Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2024
Lead Product(s) : Clonidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Perigon Pharmacy 360
Deal Size : Undisclosed
Deal Type : Partnership
Details : Tris Pharma and Perigon launched a direct-to-patient program, that allows patients and caregivers access to DYANAVEL XR (amphetamine) extended-release tablets through Perigon’s digital pharmacy and receive assistance and support to help navigate their ...
Product Name : Dyanavel XR
Product Type : Small molecule
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : Amphetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Perigon Pharmacy 360
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Quillivant ER (methylphenidate) Oral Suspension and Chewable Tablet R is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Quillivant ER
Product Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2023
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cebranopadol
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : National Institute on Drug Abuse
Deal Size : $16.6 million
Deal Type : Funding
Details : Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment f...
Product Name : TRN-228
Product Type : Small molecule
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Cebranopadol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : National Institute on Drug Abuse
Deal Size : $16.6 million
Deal Type : Funding
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain.
Product Name : TRN-228
Product Type : Small molecule
Upfront Cash : Not Applicable
December 13, 2022
Lead Product(s) : Cebranopadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable